Norepinephrine Bitartrate


Baxter Healthcare Corporation
Human Prescription Drug
NDC 36000-162
Norepinephrine Bitartrate is a human prescription drug labeled by 'Baxter Healthcare Corporation'. National Drug Code (NDC) number for Norepinephrine Bitartrate is 36000-162. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Norepinephrine Bitartrate drug includes Norepinephrine Bitartrate - 1 mg/mL . The currest status of Norepinephrine Bitartrate drug is Active.

Drug Information:

Drug NDC: 36000-162
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Norepinephrine Bitartrate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Norepinephrine Bitartrate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Baxter Healthcare Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:NOREPINEPHRINE BITARTRATE - 1 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Apr, 2012
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA040859
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Baxter Healthcare Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:242969
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:IFY5PE3ZRW
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Catecholamine [EPC]
Catecholamines [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
36000-162-1010 AMPULE in 1 CARTON (36000-162-10) / 4 mL in 1 AMPULE (36000-162-01)01 Apr, 2012N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Norepinephrine bitartrate norepinephrine bitartrate norepinephrine bitartrate norepinephrine sodium chloride nitrogen

Drug Interactions:

Drug interactions: cyclopropane and halothane anesthetics increase cardiac autonomic irritability and therefore seem to sensitize the myocardium to the action of intravenously administered epinephrine or norepinephrine. hence, the use of norepinephrine during cyclopropane and halothane anesthesia is generally considered contraindicated because of the risk of producing ventricular tachycardia or fibrillation. the same type of cardiac arrhythmias may result from the use of norepinephrine in patients with profound hypoxia or hypercarbia. norepinephrine should be used with extreme caution in patients receiving monoamine oxidase inhibitors (maoi) or antidepressants of the triptyline or imipramine types, because severe, prolonged hypertension may result.

Indications and Usage:

Indications and usage for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). as an adjunct in the treatment of cardiac arrest and profound hypotension.

Warnings:

Warnings norepinephrine should be used with extreme caution in patients receiving monoamine oxidase inhibitors (maoi) or antidepressants of the triptyline or imipramine types, because severe, prolonged hypertension may result.

Dosage and Administration:

Dosage and administration norepinephrine bitartrate injection is a concentrated, potent drug which must be diluted in dextrose containing solutions prior to infusion. an infusion of norepinephrine should be given into a large vein (see precautions). restoration of blood pressure in acute hypotensive states blood volume depletion should always be corrected as fully as possible before any vasopressor is administered. when, as an emergency measure, intraaortic pressures must be maintained to prevent cerebral or coronary artery ischemia, norepinephrine can be administered before and concurrently with blood volume replacement. diluent: norepinephrine should be diluted in 5 percent dextrose injection or 5 percent dextrose and sodium chloride injections. these dextrose containing fluids are protection against significant loss of potency due to oxidation. administration in saline solution alone is not recommended. whole blood or plasma, if indicated to increase blood volume, should be administ
ered separately (for example, by use of a y-tube and individual containers if given simultaneously). average dosage: add a 4 ml ampul (4 mg) of norepinephrine to 1,000 ml of a 5 percent dextrose containing solution. each ml of this dilution contains 4 mcg of the base of norepinephrine. give this solution by intravenous infusion. insert a plastic intravenous catheter through a suitable bore needle well advanced centrally into the vein and securely fixed with adhesive tape, avoiding, if possible, a catheter tie-in technique as this promotes stasis. an iv drip chamber or other suitable metering device is essential to permit an accurate estimation of the rate of flow in drops per minute. after observing the response to an initial dose of 2 ml to 3 ml (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low normal blood pressure (usually 80 mm hg to 100 mm hg systolic) sufficient to maintain the circulation to vital organs. in previously hypertensive patients, it is recommended that the blood pressure should be raised no higher than 40 mm hg below the preexisting systolic pressure. the average maintenance dose ranges from 0.5 ml to 1 ml per minute (from 2 mcg to 4 mcg of base). high dosage: great individual variation occurs in the dose required to attain and maintain an adequate blood pressure. in all cases, dosage of norepinephrine should be titrated according to the response of the patient. occasionally much larger or even enormous daily doses (as high as 68 mg base or 17 ampules) may be necessary if the patient remains hypotensive, but occult blood volume depletion should always be suspected and corrected when present. central venous pressure monitoring is usually helpful in detecting and treating this situation. fluid intake: the degree of dilution depends on clinical fluid volume requirements. if large volumes of fluid (dextrose) are needed at a flow rate that would involve an excessive dose of the pressor agent per unit of time, a solution more dilute than 4 mcg per ml should be used. on the other hand, when large volumes of fluid are clinically undesirable, a concentration greater than 4 mcg per ml may be necessary. duration of therapy: the infusion should be continued until adequate blood pressure and tissue perfusion are maintained without therapy. infusions of norepinephrine should be reduced gradually, avoiding abrupt withdrawal. in some of the reported cases of vascular collapse due to acute myocardial infarction, treatment was required for up to six days. adjunctive treatment in cardiac arrest infusions of norepinephrine are usually administered intravenously during cardiac resuscitation to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means. [norepinephrine's powerful beta-adrenergic stimulating action is also thought to increase the strength and effectiveness of systolic contractions once they occur.] average dosage: to maintain systemic blood pressure during the management of cardiac arrest, norepinephrine is used in the same manner as described under restoration of blood pressure in acute hypotensive states. parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit. do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate. avoid contact with iron salts, alkalis, or oxidizing agents.

Contraindications:

Contraindications norepinephrine bitartrate injection, usp should not be given to patients who are hypotensive from blood volume deficits except as an emergency measure to maintain coronary and cerebral artery perfusion until blood volume replacement therapy can be completed. if norepinephrine bitartrate injection, usp is continuously administered to maintain blood pressure in the absence of blood volume replacement, the following may occur: severe peripheral and visceral vasoconstriction, decreased renal perfusion and urine output, poor systemic blood flow despite "normal" blood pressure, tissue hypoxia, and lactate acidosis. norepinephrine bitartrate injection, usp should also not be given to patients with mesenteric or peripheral vascular thrombosis (because of the risk of increasing ischemia and extending the area of infarction) unless, in the opinion of the attending physician, the administration of norepinephrine bitartrate injection, usp is necessary as a life-saving procedure. cyclopropane and halothane anesthetics increase cardiac autonomic irritability and therefore seem to sensitize the myocardium to the action of intravenously administered epinephrine or norepinephrine. hence, the use of norepinephrine bitartrate injection, usp during cyclopropane and halothane anesthesia is generally considered contraindicated because of the risk of producing ventricular tachycardia or fibrillation. the same type of cardiac arrhythmias may result from the use of norepinephrine bitartrate injection, usp in patients with profound hypoxia or hypercarbia.

Adverse Reactions:

Adverse reactions the following reactions can occur: body as a whole: ischemic injury due to potent vasoconstrictor action and tissue hypoxia. cardiovascular system: bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias. nervous system: anxiety, transient headache. respiratory system: respiratory difficulty. skin and appendages: extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. ov
erdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

Drug Interactions:

Drug interactions: cyclopropane and halothane anesthetics increase cardiac autonomic irritability and therefore seem to sensitize the myocardium to the action of intravenously administered epinephrine or norepinephrine. hence, the use of norepinephrine during cyclopropane and halothane anesthesia is generally considered contraindicated because of the risk of producing ventricular tachycardia or fibrillation. the same type of cardiac arrhythmias may result from the use of norepinephrine in patients with profound hypoxia or hypercarbia. norepinephrine should be used with extreme caution in patients receiving monoamine oxidase inhibitors (maoi) or antidepressants of the triptyline or imipramine types, because severe, prolonged hypertension may result.

Use in Pregnancy:

Pregnancy category c: animal reproduction studies have not been conducted with norepinephrine. it is also not known whether norepinephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. norepinephrine should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use: safety and effectiveness in pediatric patients has not been established.

Geriatric Use:

Geriatric use: clinical studies of norepinephrine bitartrate injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. norepinephrine infusions should not be administered into the veins in the leg in elderly patients (see precautions , general).

Overdosage:

Overdosage overdosage with norepinephrine may result in headache, severe hypertension, reflex bradycardia, marked increase in peripheral resistance, and decreased cardiac output. in case of accidental overdosage, as evidenced by excessive blood pressure elevation, discontinue norepinephrine until the condition of the patient stabilizes.

Description:

Description norepinephrine (sometimes referred to as l-arterenol/levarterenol or l-norepinephrine) is a sympathomimetic amine which differs from epinephrine by the absence of a methyl group on the nitrogen atom. norepinephrine bitartrate is (-)-α-(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate and has the following structural formula: norepinephrine is supplied in sterile aqueous solution in the form of the bitartrate salt to be administered by intravenous infusion following dilution. norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids. each ml contains the equivalent of 1 mg base of norepinephrine, sodium chloride for isotonicity. it has a ph of 3 to 4.5. the air in the ampules has been displaced by nitrogen gas. structure 1

Clinical Pharmacology:

Clinical pharmacology norepinephrine functions as a peripheral vasoconstrictor (alpha-adrenergic action) and as an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility: studies have not been performed.

How Supplied:

How supplied norepinephrine bitartrate injection, usp, contains the equivalent of 4 mg base of norepinephrine per each 4 ml ampule (1 mg/ml), and is available as follows: ain00610 ndc 36000-162-10 ampules of 4 ml in shelf carton of 10 store at 25°c (77°f); excursions permitted to 15 to 30°c (59 to 86°f) [see usp controlled room temperature]. retain in carton until time of use. protect from light.

Package Label Principal Display Panel:

Package label.principal display panel - 4mg/ml ain00610 ndc: 36000-162-01 norepinephrine bitartrate injection, usp 4 mg/4 ml (1 mg per ml) rx only contains no sulfites - preservative free each ml contains: norepinephrine bitartrate equal to 1mg norepinephrine base. for iv infusion only - dilute before use. protect from light. directions: see insert. baxter deerfield, il 60015 usa 68797 02 2018-10-31 container 2

Package label.principal display panel - 4mg/ml sterile injection ain00610 ndc : 36000-162-10 10 ampules 4 ml each norepinephrine bitartrate injection, usp rx only 4 mg/4 ml (1 mg per ml) contains no sulfites – preservative free warning: this is a potent drug. dosage should be controlled by frequent determination of blood pressure. do not leave patient unattended during administration. avoid extravasation. read package insert carefully. for intravenous infusion only. dilute before use. discard unused portion. usual dosage and dilution information - see package insert. do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate. avoid contact with iron salts, alkalis, or oxidizing agents. each ml contains: norepinephrine bitartrate, equivalent to 1 mg norepinephrine base, sodium chloride for isotonicity. the air in the ampules has been displaced by nitrogen gas. these ampules are easy break ampules. store at 25°c (77°f); excursions permitted to 15 to 30°c (59 to 86°f) [see usp controlled room temperature]. retain in carton until time of use. protect from light. manufactured by: sintetica s.a. switzerland manufactured for: baxter healthcare corporation deerfield, il 60015 usa 66797 02 2018-10-31 carton 3


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.